Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version

Go to Patient Version

Changes to This Summary (11/13/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Histopathologic, Immunologic, and Cytogenetic Characteristics of Langerhans Cell Histiocytosis (LCH)

Added text to state that other BRAF mutations that result in signal activation have been described (cited Héritier et al. as reference 22).

Adult LCH

Revised text to state that a study that correlated lung computed tomography findings and lung biopsy results in 27 patients with pulmonary LCH observed that thin-walled and bizarre cysts had active Langerhans cells and eosinophils.

Treatment of Adult LCH

Added text to state that a study of 27 patients with pulmonary LCH observed that 52% of patients improved after a mean follow-up period of 14 months; most patients improved with smoking cessation, and some patients improved with steroid treatment. Four patients had stable disease at a mean follow-up of 26 months, and nine patients demonstrated disease progression during the mean follow-up of 22 months (cited Kim et al. as reference 5).

Added Chu as reference 29.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Adult LCH

Next section >
About This PDQ Summary